Topic: Pharmaceutical Research and Manufacturers of America

All Content

Newt Gingrich pushes back against critics

Faced with growing criticism about his many years as a Washington insider, Newt Gingrich has launched a new website "Answering the Attacks." But some across the political spectrum continue to raise questions about his professional and personal record.
The Vote
Being a Washington insider has made Newt Gingrich a wealthy man

After 20 years as a member of Congress, including two terms as House speaker, Newt Gingrich did not go back home to Georgia. Instead, he kept his hand in the political game, making lots of money consulting for corporations.
Robert Reich
Hey, big business, push back against the tea party!

It's easy to understand the anti-Fed attitudes and nativism of tea party supporters: economic fears drive people to scapegoat institutions and outsiders. But why aren't business leaders responding?
Congress wants details about Obama's healthcare reform deals

Democrat Rep. Henry Waxman joins Republicans in calling for details on any deals the White House may have made with special interests in crafting healthcare reform legislation. Did industry groups get special treatment?
Healthcare reform: Obama cut private deals with likely foes

President Obama struck agreements with insurers, doctors, drug companies, and hospitals to keep them from turning against healthcare reform. What are they?
No 'robust' public option in House healthcare reform bill

Speaker Nancy Pelosi unveiled the House's healthcare reform bill Thursday. She had to compromise with conservative Democrats on the public option in order to win their votes.
How Washington lobbyists peddle power

The equivalent of six health-care lobbyists for every member of Congress are registered for this year's biggest political battle.
Baucus’s Senate panel whacks away at healthcare amendments

Finance Committee cuts 61 amendments, leaving just 503 to go. Among the major issues remaining: a public option.
Supreme Court takes up drug warning labels

The case pits a Vermont musician who lost a limb against a pharmaceutical giant.